Terapia anty-VEGF w cukrzycowym obrzęku plamki
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2015
Słowa kluczowe:
cukrzyca, cukrzycowy obrzęk plamki, terapia anty-VEGF, inhibitory VEGF, laseroterapia, ranibizumab, afilbercept, terapia skojarzona
##plugins.themes.bootstrap3.article.main##
Abstrakt
Obrzęk plamki jest najczęstszą przyczyną znacznego pogorszenia widzenia u pacjentów z cukrzycą. Jednym z głównych czynników odpowiedzialnych za gromadzenie się płynu w obszarze plamkowym i powstawanie obrzęku jest wewnątrzgałkowy wzrost stężenia śródbłonkowego czynnika wzrostu naczyniowego (VEGF, vascular endothelial growth factor). Wyniki licznych badań potwierdzają lepsze efekty terapii anty-VEGF ranibizumabem, bewacyzumabem lub afliberceptem (zarówno w monoterapii, jak i terapii łączonej) w porównaniu z dotychczas stosowaną laseroterapią w zakresie poprawy ostrości wzroku u pacjentów z pogorszeniem widzenia w przebiegu cukrzycowego obrzęku plamki. Praca przedstawia możliwości leczenia inhibitorami anty- -VEGF w zależności od czasu trwania i postaci obrzęku, wyjściowej ostrości wzroku oraz wcześniej stosowanych metod leczenia, w celu osiągnięcia najlepszego efektu terapii u danego pacjenta.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Mozolewska-Piotrowska K. Terapia anty-VEGF w cukrzycowym obrzęku plamki. Ophthatherapy [Internet]. 30 wrzesień 2015 [cytowane 3 lipiec 2024];2(3):205-10. Dostępne na: https://journalsmededu.pl/index.php/ophthatherapy/article/view/643
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Klein R, Knudtson MD, Lee KE et al. The Wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116(3): 497-503.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal. 1998; 317: 703-13.
3. Arend O, Remky A, Elsner AE et al. Quantification of cystoid changes in diabetic maculopathy. Invest Ophthalmol Vis Sci. 1995; 36(3): 608-13.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Archives of Ophthalmology. 1985; 103(12): 1796-806.
5. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol. 2006; 142: 961-9.
6. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
7. Funatsu H, Yamashita H, Sakata K et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005; 112: 806-16.
8. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month randomized, controlled, double masked, multiceter phase II study. Diabetes Care. 2010; 33: 2399-405.
9. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615-25.
10. Brown DM, Nguyen QD, Marcus DM et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120: 2013-22.
11. Campochiaro PA, Wykoff CC, Shapiro H et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014; 121: 1783-9.
12. Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI Study: phase II primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011; 118(9): 1819-1826.
13. Korobelnik JF, Do DV, Schmidt-Erfurth U et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121: 2247-54.
14. Arevalo JF, Fromow-Guerra J, Quiriz-Mercado H et al.; The Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow up. Ophthalmology. 2007; 114: 743-50.
15. Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology. 2010; 117: 1107-18.
16. Wells JA, Glassman AR, Jampol LM et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372: 1193-203.
17. Bandello F, De Benedetto U, Knutsson KA et al. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol. 2011; 5: 1303-8.
18. Elman MJ, Bressler NM, Qin H et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2 year follow up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118: 609-14.
19. Nguyen QD, Shah SM, Khwaja AA et al. Two year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2007; 114: 1860-7.
20. Googe J, Brucker AJ, Bressler NM et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011; 31: 1009-27.
21. Sohn HJ, Han DH, Kim TI et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152: 686-94.
22. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116: 1142-50.
23. Synek S, Vojnikovic B. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Coll Antropol. 2010; 34(2): 99-103.
24. Cunha-Vaz J, Ashton P, Lezzi R et al. Sustained delivery fluocinolone acetonide vitreous implants: long term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014; 121: 1892-903.
25. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or a new trend? Curr Diab Rep. 2012; 12: 364-75.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal. 1998; 317: 703-13.
3. Arend O, Remky A, Elsner AE et al. Quantification of cystoid changes in diabetic maculopathy. Invest Ophthalmol Vis Sci. 1995; 36(3): 608-13.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Archives of Ophthalmology. 1985; 103(12): 1796-806.
5. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol. 2006; 142: 961-9.
6. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
7. Funatsu H, Yamashita H, Sakata K et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005; 112: 806-16.
8. Massin P, Bandello F, Garweg JG et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month randomized, controlled, double masked, multiceter phase II study. Diabetes Care. 2010; 33: 2399-405.
9. Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118: 615-25.
10. Brown DM, Nguyen QD, Marcus DM et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120: 2013-22.
11. Campochiaro PA, Wykoff CC, Shapiro H et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014; 121: 1783-9.
12. Do DV, Schmidt-Erfurth U, Gonzalez VH et al. The DA VINCI Study: phase II primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011; 118(9): 1819-1826.
13. Korobelnik JF, Do DV, Schmidt-Erfurth U et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121: 2247-54.
14. Arevalo JF, Fromow-Guerra J, Quiriz-Mercado H et al.; The Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow up. Ophthalmology. 2007; 114: 743-50.
15. Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology. 2010; 117: 1107-18.
16. Wells JA, Glassman AR, Jampol LM et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372: 1193-203.
17. Bandello F, De Benedetto U, Knutsson KA et al. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol. 2011; 5: 1303-8.
18. Elman MJ, Bressler NM, Qin H et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2 year follow up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118: 609-14.
19. Nguyen QD, Shah SM, Khwaja AA et al. Two year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2007; 114: 1860-7.
20. Googe J, Brucker AJ, Bressler NM et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011; 31: 1009-27.
21. Sohn HJ, Han DH, Kim TI et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152: 686-94.
22. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009; 116: 1142-50.
23. Synek S, Vojnikovic B. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Coll Antropol. 2010; 34(2): 99-103.
24. Cunha-Vaz J, Ashton P, Lezzi R et al. Sustained delivery fluocinolone acetonide vitreous implants: long term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014; 121: 1892-903.
25. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or a new trend? Curr Diab Rep. 2012; 12: 364-75.